| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a6462bd03c017c6ed99e9290a560445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_468df7104108619adb64bcfaf5c24d63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2a0e759e7b4ef073bcd9d5f2c80fb73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4817c2a3644879de698f7d4d5633b9a6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-32 |
| filingDate |
2010-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84fbf7bec5f4678b0a3b3c6fb45921f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20b83f30f44b4fa6b1afd9f9a8c5cf1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a280edc1284294d8d94f84c13315e90f |
| publicationDate |
2010-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010144794-A1 |
| titleOfInvention |
Baculovirus-expressed fusion polypeptide vaccines with enhanced immunogenicity and uses thereof |
| abstract |
The present invention is generally related to a method of baculovirus expression of a LFn-fusion protein for use in delivering antigens across the membrane of a cell to elicit a strong response of cell-mediated immunity (CMI) to the antigen portion of the LFn-fusion protein. One aspect of the present invention relates to the methods of use of a baculovirus expression system to produce N-glycosylated forms of LFn and LFn fusion polypeptides, which are more effective than non-glycosylated forms of the fusion proteins for delivering antigens across the membrane of a eukaryotic cell to elicit a strong CMI. Another aspect relates to methods and compositions to elicit a CMI response in a cell to a target antigen, comprising contacting the cell with a target antigen fused to a LFn polypeptide, wherein the target antigen and/or the LFn polypeptide are N-glycosylated. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10837970-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11624750-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011156594-A3 |
| priorityDate |
2009-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |